Global central nervous system market to surpass $80b in 2025

It is the fifth-fastest growing therapy area for the year.

The global central nervous system (CNS) market is projected to exceed $80b in sales in 2025, marking its first return to this level since 2013, said GlobalData.

The resurgence positions CNS as the fifth-fastest growing therapy area for the year, driven by strong multiple sclerosis (MS) drug sales and advancements in psychiatric drug development.

Moreover, developments in neuroimmunology and neurodegeneration are contributing to market growth.

High research and development costs, clinical challenges, and setbacks in Alzheimer’s disease and amyotrophic lateral sclerosis had previously slowed investment in CNS therapeutics, said Eleni Tokali, Pharma Analyst at GlobalData.

“The CNS market is at a turning point. With breakthroughs in psychiatry, Alzheimer’s, and MS, pharma is moving towards a more diversified and sustainable approach to neurological and psychiatric drug development,” Tokali added.